Literature DB >> 17703333

Severe invalidating pain syndrome associated with benznidazole therapy for Chagas' disease.

Concepción Moll1, Pilar Peris, Asunción Moreno, José Muñoz, Nuria Guañabens.   

Abstract

Chagas' disease is an endemic parasitic disease and constitutes an important health problem in Latin American countries. The increasing number of immigrants from these countries has resulted in a rise in diagnosis and consequently in the treatment of this disease in developed countries not familiar with this condition. Currently, benznidazole is used for treatment of this condition. However, undesirable effects have been reported with this treatment, and there are few data about continuous long-term use of this drug. We describe a case of invalidating pain syndrome in a 31-year-old Bolivian woman with Chagas' disease while receiving benznidazole therapy. Because of the number of cases with this condition will probably increase because of immigration, a better understanding of the side effects of the treatment of this disease is essential.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17703333     DOI: 10.1007/s10067-007-0715-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  11 in total

Review 1.  An update on Chagas disease (human American trypanosomiasis).

Authors:  A Moncayo; M I Ortiz Yanine
Journal:  Ann Trop Med Parasitol       Date:  2006-12

Review 2.  American trypanosomiasis (Chagas' disease)--a tropical disease now in the United States.

Authors:  L V Kirchhoff
Journal:  N Engl J Med       Date:  1993-08-26       Impact factor: 91.245

3.  Short report: benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up.

Authors:  Ana Lucia S S Andrade; Celina M T Martelli; Renato M Oliveira; Simonne A Silva; Andréa I S Aires; Lea M T Soussumi; Dimas T Covas; Luiz S Silva; João G Andrade; Luiz R Travassos; Igor C Almeida
Journal:  Am J Trop Med Hyg       Date:  2004-11       Impact factor: 2.345

4.  Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial.

Authors:  Rodolfo Viotti; Carlos Vigliano; Bruno Lococo; Graciela Bertocchi; Marcos Petti; María Gabriela Alvarez; Miriam Postan; Alejandro Armenti
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

Review 5.  Clinical and epidemiological aspects of Chagas disease.

Authors:  A Prata
Journal:  Lancet Infect Dis       Date:  2001-09       Impact factor: 25.071

6.  Long term evaluation of etiological treatment of chagas disease with benznidazole.

Authors:  J Romeu Cancado
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2002 Jan-Feb       Impact factor: 1.846

7.  Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.

Authors:  A L de Andrade; F Zicker; R M de Oliveira; S Almeida Silva; A Luquetti; L R Travassos; I C Almeida; S S de Andrade; J G de Andrade; C M Martelli
Journal:  Lancet       Date:  1996-11-23       Impact factor: 79.321

Review 8.  Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease).

Authors:  J A Castro; E G Diaz de Toranzo
Journal:  Biomed Environ Sci       Date:  1988-06       Impact factor: 3.118

9.  Serodiagnosis of chronic and acute Chagas' disease with Trypanosoma cruzi recombinant proteins: results of a collaborative study in six Latin American countries.

Authors:  Eufrosina S Umezawa; Alejandro O Luquetti; Gabriela Levitus; Carlos Ponce; Elisa Ponce; Diana Henriquez; Susana Revollo; Bertha Espinoza; Octavio Sousa; Baldip Khan; José Franco da Silveira
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

10.  [Treatment of Chagas disease with benznidazole and thioctic acid].

Authors:  Sergio Sosa-Estani; Alejandro Armenti; Graciela Araujo; Rodolfo Viotti; Bruno Lococo; Basilio Ruiz Vera; Carlos Vigliano; Ana M de Rissio; Elsa L Segura
Journal:  Medicina (B Aires)       Date:  2004       Impact factor: 0.653

View more
  1 in total

1.  Arthritis and benznidazole: more closely related than we thought.

Authors:  E Aldasoro; M J Pinazo; I Oliveira; J Munoz; E Posada; A Requena-Méndez; N Serret; J Gascon
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.